Asthma Clinical Trial
— G2PThe primary hypothesis the investigators will test is that that improving asthma guideline implementation and providing patients with a unified asthma management plan using a multi-component and multilevel intervention will improve patient-centered asthma outcomes compared to health plan case management, passive guideline dissemination and provider education.
| Status | Enrolling by invitation |
| Enrollment | 550 |
| Est. completion date | October 2016 |
| Est. primary completion date | October 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 5 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Age 5-75 - Provider-verified diagnosis of asthma - Have uncontrolled asthma - Primary language of English,Spanish or Vietnamese - Patient of Neighborcare or HealthPoint Health - Insured by Molina Healthcare or Community Health Plan of Washington Exclusion Criteria: - Patient planning to leave Neighborcare or Healthpoint Health within the next 12 months - Household appearing to be unsafe for a visit by a community health worker - Co-existing medical conditions that make asthma control a low priority for patient management or that confound outcome measurement or that preclude participation in self-management - Participation in another asthma research study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label
| Country | Name | City | State |
|---|---|---|---|
| United States | Public Health -- Seattle & King County | Seattle | Washington |
| Lead Sponsor | Collaborator |
|---|---|
| Public Health - Seattle and King County | Patient-Centered Outcomes Research Institute |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Symptom free days | Measured by questionnaire: Days without cough, wheeze, chest tightness, shortness of breath, nocturnal wakening from symptoms or activity limitation due to asthma in past 2 weeks. | 12 Months | No |
| Primary | Asthma control | Measured by questionnaire and spirometry. Asthma Control Adults: Asthma Control Test and EPR3 categories Asthma Control Children: cACT and EPR3 categories | 12 Months | No |
| Primary | Asthma-related Quality of Life | Measured by questionnaire. Adults: Mini Asthma Quality of Life Questionnaire Children 7-17: Pediatric Asthma Quality of Life Questionnaire Children 5-6: Pediatric Asthma Caregiver Quality of Life Scale |
12 Months | No |
| Secondary | Nocturnal wakening | Measured by questionnaire: Nights wakened in the past two weeks due to asthma. | 12 Months | No |
| Secondary | Asthma exacerbations | Measured by questionnaire: Need for oral steroids (3+ day course), hospitalization, ED visit or unscheduled clinic visit for worsening asthma in past 12 months | 12 Months | Yes |
| Secondary | Pulmonary function | Measured by spirometry: Post-bronchodilator FEV1 and FEV1 /FVC and change in pre-post bronchodilator FEV1 and FEV1 /FVC182 using EasyOne Diagnostic spirometer | 12 Months | No |
| Secondary | FeNO (Fractional exhaled Nitric Oxide) | Measured by portable handheld device: Online measurement of ppb in exhaled breath at 50 L/s (<25 ppb indicates normal value.) | 12 Months | No |
| Secondary | Beta-agonist use | Measured by questionnaire and claims data: Days using Beta-agonist medication in past 2 weeks | 12 Months | No |
| Secondary | Oral steroid use | Measured by questionnaire and claims data: Courses of steroids (3+ day course) in past 12 months | 12 Months | No |
| Secondary | Controller use | Measured by claims data: Controller to total asthma medication ratio > 0.5 | 12 Months | No |
| Secondary | Asthma-related urgent health services utilization | Measured by questionnaire and administrative data: Urgent clinic visits, emergency department visits, and hospitalizations during past three months and past year | 12 Month | Yes |
| Secondary | Missed work or school days | Measured by questionnaire: Number of school or work days missed in past two weeks. | 12 Months | No |
| Secondary | General Health Status | Measured by questionnaire: Adults: SF-12 Health Survey Children: SF -10 Health Survey |
12 Months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|